Sunshine Biopharma’s parent company, Advanomics Corp., has entered an agreement to acquire Garmen Laboratories, a GMP lab that provides pharmaceutical manufacturing and testing services. Garmen is headquartered in a 50,000-sq.-ft. facility in Montreal and delivers solutions that can help detect, identify and quantify trace-level chemical components in the nutraceutical and pharmaceutical industries. Garmen is an FDA-registered facility with a quality assurance program meets 21CFR211, GMP, and ISO 17025 standards.
Garmen will manufacture 1 kilogram of Adva-27a, Sunshine's flagship drug candidate in development for multidrug resistant cancers. The 1-kilogram GMP material will be used to complete the remaining studies required to file an IND with the FDA, and conduct the Phase I trial of Adva-27a in breast cancer.
"We are extremely pleased with the acquisition of Garmen Laboratories as it puts us in a prime position to continue to advance our novel cancer drug," said Dr. Steve N. Slilaty, chief executive officer of Sunshine Biopharma. "We are excited that our methodical business plan in the development of Adva-27a is coming to fruition. The recent grants have us in a sound financial condition and the new acquisition provides us with complete control of the manufacturing process, an envious position for any small biotechnology company."